Carboplatin (CBDCA, JM-8) and VP-16-213 in previously untreated patients with small-cell lung cancer

J. F. Bishop, D. Raghavan, R. Stuart-Harris, G. Morstyn, R. Aroney, R. Kefford, K. Yuen, J. Lee, P. Gianoutsos, I. N. Olver, J. Zalcberg, D. Ball, C. Bull, R. Fox

Research output: Contribution to journalArticlepeer-review

93 Citations (Scopus)

Abstract

The efficacy and toxicity of carboplatin 100 mg/m2, administered intravenously (IV) daily x 3, and VP-16-213 120 mg/m2, IV daily x 3, administered every 28 days for six courses, was assessed in 94 (36 limited stage, 58 extensive stage) previously untreated patients with small-cell lung cancer. Mediastinal irradiation using 50 Gy in 25 fractions was given to all limited-stage patients with a complete (CR) or partial response (PR) after three chemotherapy courses. Cranial irradiation was administered to all patients with CR. Objective responses were seen in 77% (CR 40%, PR 37%) of patients with limited-stage and 58% (CR, 9%; PR, 49%) with extensive-stage disease. Median relapse-free survival for objective responders with limited stage was 14.6 months and 7.9 months for extensive-stage patients. Median relapse-free survival following CR was 15.4 months and 8.5 months for PR. Median survival was 15.3 months for limited-stage and 8.1 months for extensive-stage patients. The combination was well tolerated with mild nausea or less (World Health Organization [WHO] grade 0 or 1) in 62% of patients and minimal mucositis, renal, neurotoxicity, or ototoxicity. Neutropenia <1.0 x 109/L (WHO grade 3 or 4) was seen in 63% of patients, with two deaths from infection while neutropenic. The combination of carboplatin and VP-16-213 is a new, active program with low toxicity when applied intensively in previously untreated patients with small-cell lung cancer.

Original languageEnglish
Pages (from-to)1574-1578
Number of pages5
JournalJournal of Clinical Oncology
Volume5
Issue number10
Publication statusPublished - 1987
Externally publishedYes

Fingerprint Dive into the research topics of 'Carboplatin (CBDCA, JM-8) and VP-16-213 in previously untreated patients with small-cell lung cancer'. Together they form a unique fingerprint.

Cite this